Skip to Main Content
Main Content

Currently Accepting Nominations


Technical Expert Panels: Currently Accepting Nominations Link

This page serves as the designated site that is used to solicit nominations for technical expert panel members for CMS measure development and maintenance contractors.   Individuals with expertise in the relevant fields including clinicians, statisticians, quality improvement, methodologists, and pertinent measure developers, as well as consumers, are encouraged to submit nominations.  Person and family membership on TEPs is a very important part of the measure development process. TEP members are chosen to provide input to the measure contractor based on their personal experience and training. It is critical to the success that TEP members represent a diversity of perspectives and backgrounds.

TEPs Accepting Nominations:  

Project Title: Development and Maintenance of Quality Measures for Skilled Nursing Facility Quality Reporting Program (SNF QRP)

Dates:

The TEP nomination period opens on January 21, 2019 and closes on February 15, 2019. Please submit all nomination materials by the closing date.

Project Overview:                                                                                       

The Centers for Medicare & Medicaid Services (CMS) has contracted with RTI International to develop and maintain quality measures for the SNF QRP. The contract name is Development and Maintenance of Symptom Management Measures (HHSM-500-2013-13015I). As part of its measure development and maintenance process, CMS asks measure developers to convene groups of stakeholders and experts who contribute direction and thoughtful input to the measure developer during measure development and maintenance.

Project Objectives:

Healthcare-associated infections are an important public health and patient safety issue. Under the Quality Priority of “Making Care Safer by Reducing Harm Caused in the Delivery of Care” is the Meaningful Measure Area of Healthcare Associated Infections. To focus on the high priority domain and fill an important gap of quality measurement in this area, this project is aimed to develop a claims-based measure of healthcare-associated infections in skilled nursing facilities.  

The purpose of this TEP is to inform the direction and development of a claims-based measure of healthcare-associated infections in skilled nursing facilities.

TEP Objective:

  • To obtain input on the options for a claims-based measure of healthcare-associated infections in skilled nursing facilities

TEP Requirements:

We are seeking a TEP of approximately 10-12 individuals with the following perspectives and areas of expertise:

Subject matter expertise:

  • Policies and clinical practices in skilled nursing facilities and nursing homes
  • Infectious diseases
  • Consumer/patient/family perspective
  • Quality measurement science and methodology
  • Health care disparities
  • Performance measurement
  • Quality improvement
  • Purchaser perspective

Potential TEP members must be aware that participation on the TEP is voluntary. As such, individuals wishing to participate on the TEP should understand that their input will be recorded in the meeting minutes. Proceedings of the TEP will be summarized in a report that is disclosed to the general public. If a participant has disclosed private, personal data by his or her own choice, then that material and those communications are not deemed to be covered by patient-provider confidentiality. If patient participants (only) wish to keep their names confidential, that request can be accommodated. Any questions about confidentiality will be answered by the TEP organizers.

All potential TEP members must disclose any current and past activities that may pose a potential conflict of interest for performing the tasks required of the TEP. All potential TEP members should be able to commit to the anticipated time frame needed to perform the functions of the TEP.

Patient Nominees:

RTI International is seeking patients to participate on a TEP. We are seeking individuals who received skilled nursing care in a nursing home to join the TEP. Individuals who have received skilled nursing care in a nursing home can provide unique and essential input on quality measures based on their own experience and perspective. Patient nominees should submit a completed and signed TEP Nomination Form and letter of interest as described below but are not required to submit a curriculum vitae.

TEP Expected Time Commitment:

  • The TEP is expected to meet once for a 1-day, in-person meeting in Baltimore, MD, in April 2019.
  • Input prior to and after the in-person meeting may be sought via email, as needed.
  • Follow-up meetings via webinar or telephone as needed.

Required Information:

  • A completed and signed TEP Nomination form located in the download section below.
    • The nomination form includes a consent and confidentiality statement.
  • A letter of interest (not to exceed two pages) highlighting experience/knowledge relevant to the expertise described above and involvement in measure development.
  • Curriculum vitae or a summary of relevant experience for a maximum of 10 pages.
    • Patient participants are not required to submit a curriculum vitae and may elect to keep their names confidential in public documents.

The Nomination forms and proposed TEP Charter are found in the download section below.

If you wish to nominate yourself or other individuals for consideration, please complete the form and email it to: Kelly Hughes snfhai@rti.org.

Back to Top

Project Title: Measuring Outcomes in Orthopedics Routinely (MOOR)

Dates:

The Technical Expert Panel (TEP) nomination period opens on January 21, 2019 and closes on February 19, 2019. Please submit all nomination materials by the closing date.

Project Overview:

The Centers for Medicare & Medicaid Services (CMS) has entered into a cooperative agreement with Brigham and Women’s Hospital (BWH) to develop and refine electronic clinical quality measures (eCQMs) in the areas of orthopedic surgery outcomes and medication safety; and to develop and refine Patient Reported Outcome Performance Measures (PRO-PMs) related to orthopedic surgery clinical care. The cooperative agreement project name is Measuring Outcomes in Orthopedics Routinely (MOOR). The contract number is 1V1CMS331637-01-00. As part of its measure development process, BWH is convening groups of stakeholders and experts who contribute direction and thoughtful input to the measure developer during measure development and maintenance.

Project Objectives:

  1. Develop and refine electronic clinical quality measures (eCQMs) in the areas of orthopedic surgery outcomes and medication safety.
  2. Develop and refine Patient Reported Outcome Performance Measures (PRO-PMs) related to orthopedic surgery clinical care.

Project Goals:

  1. Convert one existing National Quality Foundation (NQF) approved measures for complication following Total Hip Arthroplasty and Total Knee Arthroplasty (THA/TKA) to an electronic clinical quality measure (eCQMs):
    1. Opioids NQF 2940: Use of opioids at high dosage in persons without cancer following THA/TKA
  2. Develop three new eCQMs to address THA/TKA orthopedic surgery patient safety practice and measurement gaps:
    1. Opioids: Hospital level risk-standardized medication side-effect rate following THA/TKA;
      1. Opioid respiratory depression
      2. Opioid extended use
    2. Anticoagulants: Hospital level risk-standardized medication side-effect rate following THA/TKA);
      1. Anticoagulant bleeding
  3. Convert an existing and valid Patient Reported Outcome Measures (PROMs) related to functional status following THA to Patient Reported Outcome Performance Measure (PRO-PM) as measured by one or more of the following: PROMIS 10 Global Function, PROMIS Physical Function 10, HOOS-PS (Short Form)
  4. Develop a new PRO-PM related to care goal achievement following orthopedic surgery: patient perceptions regarding care goal achievement following THA and/or TKA.
  5. Explore the anticipated efficacy, costs, and benefits of our proposed eCQMs and PRO-PMs to our study population (i.e., Medicare fee for service beneficiaries undergoing elective procedures).

         

        TEP Requirements:

        We are seeking a TEP of approximately seven individuals with differing perspectives and areas of expertise, such as familiarity and experience with orthopedic surgical procedures and outcomes, specifically total joint arthroplasty, patient reported outcome measures and overall measure development expertise. The TEP will provide critical orthopedic and measure development expertise through ongoing consultation to research staff throughout the measure development life cycle. The TEP will be composed of individuals with differing areas of expertise and perspectives, such as familiarity and experience with orthopedic surgical procedures and outcomes, specifically total joint arthroplasty, patient reported outcome measures and overall measure development expertise.

        Subject matter expertise is sought in relevant fields such as:

        • Orthopedic clinical outcomes
        • Electronic clinical quality measures (eCQMs), and patient reported outcome measures (PROMs) related to total joint arthroplasty procedures.
        • Implementers of Electronic Health Record (EHR) systems—clinicians with personal knowledge of EHR workflow
        • Clinical informaticists
        • EHR/Information Technology (IT) vendors
        • Programmers
        • Coding experts
        • Other measure developers—the collaborative process encouraged by CMS
        • Current EHR users (e.g., staff from measure testing sites)
        • Consumer/patient/family (caregiver) perspective
        • Performance measurement
        • Quality improvement

        Potential TEP members must be aware that participation on the TEP is voluntary. As such, individuals wishing to participate on the TEP should understand that their input will be recorded in the meeting minutes. Proceedings of the TEP will be summarized in a report that is disclosed to the general public. If a participant has disclosed private, personal data by his or her own choice, then that material and those communications are not deemed to be covered by patient-provider confidentiality. If patient participants (only) wish to keep their names confidential, that request can be accommodated. Any questions about confidentiality will be answered by the TEP organizers.

        All potential TEP members must disclose any current and past activities that may pose a potential conflict of interest for performing the tasks required of the TEP. All potential TEP members should be able to commit to the anticipated time frame needed to perform the functions of the TEP.

        Patient Nominees:

        Brigham and Women’s Hospital is seeking patients to participate on a TEP. We are seeking patients who have had experience with Total Joint Replacement surgeries, specifically Total Hip Arthroplasty and/or Total Knee Arthroplasty (Hip or Knee replacement) surgery within the past two years, to join the TEP. Patients who have had experience with Hip or Knee Replacement surgery can provide unique and essential input on quality measures based on their own experience and perspective.

        Patient nominees should submit a completed and signed TEP Nomination Form and letter of interest as described below but are not required to submit a curriculum vitae.

        TEP Expected Time Commitment:

        The duration of the measure development project is for a total of three years, from September 14, 2018 until September 13, 2021. The TEP will convene at least 4 times per year. One in-person meeting will be held each project year, and up to three virtual conferences of 1 to 3 hours may also be held through webinar and teleconference capability during each year of the term of service. Dates for the webinar/teleconference meetings will be determined based on need and member availability. Members are expected to convene in person for an initial TEP meeting in Boston, Massachusetts on a date to be determined in Spring ‘18. The meeting will last 1 full day. Project year one is 9/14/18-9/13/19; year two is 9/14/19-9/13/20; and year three is 9/14/20-9/13/21. The TEP will convene at least 4 times per year for the duration of the project from 9/14/18-9/13/21.

        The timeframe for measure development activities is as follows:

        Phase I- Measure Conceptualization (iterative): September ’18-September ‘21

        Phase II- Measure Specification: September ’18- November ‘19

        Phase III- Measure Testing: September ’18- November ‘19

        Phase IV- Measure Implementation: November ’19- September ‘21

        Required Information:

        A completed and signed TEP Nomination form located in the download section below.

        The nomination form includes a consent and confidentiality statement.

        A letter of interest (not to exceed two pages) highlighting experience/knowledge relevant to the expertise described above and involvement in measure development. Consumer/patient/family (caregiver) applicants/nominees are not expected to have experience in measure development.

        Curriculum vitae or a summary of relevant experience for a maximum of 10 pages. Consumer/patient/family (caregiver) applicants/nominees are not required to submit a curriculum vitae.

        The Nomination forms and proposed TEP Charter are found in the download section below.

        If you wish to nominate yourself or other individuals for consideration, complete the form and email it to Alexandra Businger MPH at Brigham and Women’s Hospital: abusinger@bwh.harvard.edu.

        Project Title: Practitioner Level Opioid Safety Measure Development

        Dates:

        The TEP nomination period opens on February 15, 2019 and closes on March 15, 2019. Submit all nomination materials by the closing date.

        Project Overview:

        The Centers for Medicare & Medicaid Services (CMS) has contracted with the University of Michigan Kidney Epidemiology and Cost Center to develop practitioner level measures in the area of opioid safety for dialysis patients. The contract name is Kidney Disease Quality Measure Development, Maintenance, and Support. The contract number is 75FCMC18D0041, task order number 75FCMC18F0001. As part of its measure development process, CMS asks measure developers to convene groups of stakeholders and experts who contribute direction and thoughtful input to the measure developer during measure development and maintenance.

        Project Objectives:

        The opioid epidemic has received considerable attention over the past few years. Recent reports from the Substance Abuse and Mental Health Services Administration indicate that over 11 million Americans misuse prescription opioids (SAMHSA 2017). In the ESRD population, chronic opioid use has been associated with increased emergency department visits, hospitalizations, and increased mortality (Kimmel, JASN, 2017, USRDS, 2017).   Among ESRD patients, even small doses of opioids can lead to a substantial increase in adverse outcomes (Ishida, CJASN, 2018). ESRD patients are frequently prescribed opioids and yet are particularly susceptible to opioid related complications due to associated comorbidity and frailty, as well as to potential accumulation of opioids and their metabolites which are normally cleared by functioning kidneys.

        Medication related problems from opioids can be related to suboptimal communication between providers, a lack of detailed medication reconciliation by dialysis facilities as well as a lack of understanding by providers of the effect of opiates on outcomes in dialysis patients. Addressing the misuse of opioid prescriptions thus has the potential to reduce hospitalizations, improve quality of life, and use health care resources more efficiently. Due to the frequent contact between treating ESRD Medicare Capitated Payment (MCP) practitioners, dialysis facilities’ Interdisciplinary Care Team (IDT) members and patients an increased oversight of opioid medications, even when prescribed by other providers, represents an opportunity to improve quality of care by minimizing adverse events. This TEP will evaluate the appropriateness of a measure to assess the effectiveness of the dialysis facility Interdisciplinary Team’s medication reconciliation and MCP practitioner management activities by measuring the percentage of patients who are receiving potent narcotic analgesics at high doses for prolonged periods of time. The target population will be Medicare-eligible chronic dialysis patients with Medicare Part D benefits. The provider focus will primarily be ESRD MCP providers. In addition, the TEP will consider whether a dialysis facility level measure should also be considered for development. Further, the TEP will consider and recommend appropriate risk adjustment strategies and exclusions for the measure (or measures) recommended for further development.

        TEP input will be a critical component of this measure’s development. We anticipate use of a TEP whose composition includes nephrology trained pharmacists, pain-management experts, pharmacy informatics experts, patients, nephrologists, and dialysis facility nursing staff. The TEP’s discussion will provide an opportunity to evaluate the fundamental construct and validity of this measure given the novelty of evaluation of opioid prescribing practices in the context of dialysis Interdisciplinary Team medication reconciliation, medication management, and pain assessment activities.

        TEP Requirements:

        A TEP of approximately 13-15 individuals will make recommendations regarding practitioner level measures in the area of opioid safety for dialysis patients. The TEP will be composed of individuals with differing areas of expertise and perspectives, such as:

          • Subject Matter Expertise: nephrology trained pharmacists, pain-management experts, pharmacy informatics experts, patients, nephrologists, and dialysis facility nursing staff.
          • Consumer/patient/family (caregiver) perspective
          • Performance measurement
          • Quality improvement
          • Purchaser perspective
          • Healthcare disparities

        Potential TEP members must be aware that participation on the TEP is voluntary. As such, individuals wishing to participate on the TEP should understand that their input will be recorded in the meeting minutes. Proceedings of the TEP will be summarized in a report that is disclosed to the general public. If a participant has disclosed private, personal data by his or her own choice, then that material and those communications are not deemed to be covered by patient-provider confidentiality. If potential patient participants wish to keep their names confidential, that request can be accommodated. Any questions about confidentiality will be answered by UM-KECC.

        All potential TEP members must disclose any significant financial interest or other relationships that may influence their perceptions or judgment. It is unethical to conceal (or fail to disclose) conflicts of interest. However, the disclosure requirement is not intended to prevent individuals with particular perspectives or strong points of view from serving on the TEP. The intent of full disclosure is to inform the measure developer, other TEP members, and CMS about the source of TEP members’ perspectives and how that might affect discussions or recommendations.

        Patient Nominees:

        UM-KECC is seeking patients to participate on a TEP. We are seeking patients with kidney disease who are currently on dialysis or have received dialysis in the past to join the TEP. Patients with kidney disease can provide unique and essential input on quality measures based on their own experience and perspective.

        Patient nominees should submit a completed and signed TEP Nomination Form and letter of interest as described below but are not required to submit a curriculum vitae.

        TEP Expected Time Commitment:

        • TEP members should expect to come together for one to two (1 – 2 hour) teleconference calls prior to the in-person meeting held May 2019, in Baltimore, MD
        • One one-day in-person meeting (May 2019)
        • After the in-person meeting, additional conference calls may be needed

        Required Information:

        A completed and signed TEP Nomination form located in the download section below. The nomination form includes a consent and confidentiality statement.

        A letter of interest (not to exceed two pages) highlighting experience/knowledge relevant to the expertise described above and involvement in measure development. Consumer/patient/family (caregiver) applicants/nominees are not expected to have experience in measure development.

        Curriculum vitae or a summary of relevant experience for a maximum of 10 pages. Consumer/patient/family (caregiver) applicants/nominees are not required to submit a curriculum vitae.

        The Nomination forms and proposed TEP Charter are found in the download section below.

        If you wish to nominate yourself or other individuals for consideration, complete the form and email it to: dialysisdata@umich.edu.

        Back to Top

        Project Title: MACRA Episode-Based Cost Measures – Call for Clinical Subcommittee

        Dates:

        The nomination period for ten Clinical Subcommittees active during Wave 2 of measure development opened on February 6, 2018 and closed on March 20, 2018 at midnight ET. To be considered for the first in-person meeting, all nomination materials were to be submitted before the closing date. We will, however, continue to accept nominations on a continuous basis after this date; nominees who submit their information after this date will enter a standing pool of nominees who may be selected for participation in condition- or procedure-specific workgroups convened within each Subcommittee.

        Project Overview:

        The Centers for Medicare & Medicaid Services (CMS) has contracted with Acumen, LLC to develop care episode and patient condition groups for use in cost measures to meet the requirements of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The contract name is “MACRA Episode Groups and Cost Measures.” The contract number is HHSM-500-2013-13002I, Task Order HHSM-500-T00002. As part of its measure development process, CMS asks contractors to convene groups of stakeholders and experts who contribute direction and thoughtful input to the measure developer during cost measure development and maintenance.

        Project Objectives:

        The project’s overall objective is to develop episode-based cost measures suitable for potential use in the Quality Payment Program. In Wave 2, Acumen has reconvened six of the original seven Clinical Subcommittees that participated in Wave 1 in 2017 (excluding Ophthalmologic Disease Management) as well as four new Subcommittees to contribute to the development of episode-based cost measures: Musculoskeletal Disease Management - Spine; Oncologic Disease Management - Medical, Radiation, and Surgical; Renal Disease Management; and Urologic Disease Management.

        The process for Clinical Subcommittee (CS) member involvement in measure development has been updated for Wave 2 based on the feedback we received from Subcommittee members during Wave 1 on Subcommittee size and composition. Accordingly, all members who submit their nomination materials by the deadline and who are accepted will attend the first in-person meeting and will be added to the Clinical Subcommittee. Nominees who submit their information after this date will enter a standing pool of nominees who may be selected for participation in condition- or procedure-specific workgroups convened within each Subcommittee.

        The Clinical Subcommittee is a large body of clinicians that will meet during an in-person meeting in Washington D.C. to: (i) select which episode-based cost measure to develop, and (ii) discuss the desired composition of the workgroup that will build out the selected measure.

        The Subcommittee may reconvene in future waves of measure development to provide input for additional cost measures within the Subcommittee’s clinical area.

        Once each Subcommittee selects which measure to develop, we will then create a smaller measure-specific workgroup within each Clinical Subcommittee.

        The workgroups will include 5-10 members (with a maximum of 15) whose specialty, expertise, or experience is aligned with the scope of the selected episode-based cost measure and the workgroup composition criteria discussed by the standing Subcommittee during the first in-person meeting.

        The workgroups will be formed after the Clinical Subcommittee’s in-person meeting from within the membership of the Clinical Subcommittee at large as well as the standing pool of nominees where necessary.

        Workgroup members will be expected to attend an additional in-person meeting in June 2018 (exact dates to be determined).

        For additional information about the project background or about the Wave 2 Clinical Subcommittee nomination period, please see the additional materials within the “MACRA Episode-Based Cost Measures-Call for Clinical Subcommittee” ZIP file available in the Downloads section at the bottom of this CMS webpage (direct link also available on the nomination form here).

        List of Subcommittees Participating in Wave 2:

        The list below presents the Subcommittees that we are recruiting for through this Call for Nominations. Below each Subcommittee, we list the procedural and acute inpatient medical condition episode groups in that Subcommittee’s clinical area that have been previously recommended for development by clinical stakeholders. However, this list is not limiting; the Subcommittee may recommend additional episode groups.  

        1. Cardiovascular Disease Management Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Acute Myocardial Infarction, Expired; Aortic Valve Procedure; Cardiac Arrhythmia & Conduction Disorders; Chest Pain; Coronary Artery Bypass Graft (CABG); Coronary Thrombectomy; Heart Failure & Shock; Implantable Cardiac Defibrillator (ICD) Implantation; Left Heart Catheterization; Mitral Valve Procedure; Pacemaker Implantation; Right Heart Catheterization; Supraventricular Tachycardia (SVT) Ablation; Syncope & Collapse; Thoracic Aortic Aneurysm Repair; Ventricular Tachycardia (VT) Ablation
        2. Gastrointestinal Disease Management - Medical and Surgical Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Cirrhosis & Alcoholic Hepatitis; Diagnostic Colonoscopy; Disorders Of The Biliary Tract; Esophagitis, Gastroent & Misc Digest Disorders; G.I. Hemorrhage; G.I. Obstruction; Hernia Repair (Femoral Or Inguinal); Hernia Repair (Incisional Or Ventral); Hiatal Hernia Repair; Major Gastrointestinal Disorders & Peritoneal Infections
        3. Musculoskeletal Disease Management - Non-Spine Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Ankle Fracture (No Dislocation); Bunionectomy; Femur Fracture Repair; Foot Fracture Or Dislocation; Fractures Of Hip & Pelvis; Hand Fracture Or Dislocation; Hip Arthroplasty; Humerus Fracture Repair; Knee Ligament Repair/Reconstruction; Meniscus Repair; Pelvic Fracture Repair/Treatment; Repair Of Arm Muscle Tendons (Not Including Rotator Cuff); Repair Of Foot Tendon/Ligament; Repair Of Hand Tendon/Ligament; Rotator Cuff Repair; Tibia Or Fibula Fracture Repair / Treatment; Toe Repair; Treatment of Hip Fracture/Dislocation; Treatment Of Shoulder Joint Or Clavicle Fracture/Dislocation; Wrist Fracture Treatment / Repair
        4. Musculoskeletal Disease Management - Spine Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Axial Decompression (Including Laminectomy); Spinal Fusion; Treatment of Spinal Fracture or Deformity
        5. Neuropsychiatric Disease Management Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Acute Ischemic Stroke W Use Of Thrombolytic Agent; Poisoning & Toxic Effects Of Drugs; Psychoses; Seizures; Transient Ischemia
        6. Oncologic Disease Management - Medical, Radiation, and Surgical Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Melanoma Resection; Lumpectomy or Partial Mastectomy; Simple or Modified Radical Mastectomy; Subcutaneous Mastectomy; Colonic Resection; Pancreatic Resection Excluding Pancreatic Cancer; Rectal Resection; Surgical Procedure for Gall Bladder Disease
        7. Peripheral Vascular Disease Management Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Abdominal Aortic Aneurysm Repair; Dialysis Access; Inferior Vena Cava Filter Placement; Procedure for Carotid Stenosis
        8. Pulmonary Disease Management Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Allergic Reactions; Bronchitis & Asthma; Chronic Obstructive Pulmonary Disease; Pleural Effusion; Pulmonary Edema & Respiratory Failure; Pulmonary Embolism; Respiratory Infections & Inflammations; Respiratory System Diagnosis W Ventilator Support <96 Hours; Respiratory System Diagnosis W Ventilator Support >96 Hours; Septicemia Or Severe Sepsis W Mv >96 Hours
        9. Renal Disease Management Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Endocrine Disorders; Kidney & Urinary Tract Infections; Other Kidney & Urinary Tract Diagnoses; Renal Failure
        10. Urologic Disease Management Clinical Subcommittee - This Subcommittee may contribute to the development of one or more of the following episode groups: Kidney Stone Removal or Destruction; Nephrectomy; Procedure for Benign Prostatic Hyperplasia; Prostate Cancer Treatment; Radical Cystectomy

        Returning Members

        All Subcommittee members who participated in Wave 1 in 2017 and are interested in continuing with Wave 2 of cost measure development must indicate their interest in an abbreviated nomination form shared directly with members via email. Existing members do not have to submit their nomination via the public nomination form. Please contact the Acumen measure development team if you did not receive an email.

        Future Clinical Subcommittees

        If you would like to be a part of a Clinical Subcommittee, but do not practice in any of the clinical areas we are recruiting for above, there will be future waves in which we convene additional Clinical Subcommittees. If you are interested in receiving updates regarding future Subcommittees, please provide your contact information on the MACRA Clinical Subcommittee Mailing List form.

        List of Clinicians we are Recruiting:

        Allergy/Immunology * Anesthesiology * Cardiac Electrophysiology * Cardiology * Certified Registered Nurse Anesthetist * Clinical Nurse Specialist * Clinical Psychologist * Colorectal Surgery * Critical Care (Intensivist) * Dentistry * Dermatology * Diagnostic Radiology * Emergency Medicine * Family Medicine * Gastroenterology * General Surgery * Geriatric Medicine * Hand Surgery * Hospitalists * Infectious Disease * Internal Medicine * Interventional Radiology * Interventional Cardiology * Licensed Clinical Social Worker * Mental/Behavioral Health * Nephrology * Neurology * Neurosurgical * Nurse Practitioner * Obstetrics/Gynecology * Occupational Therapy * Oncology * Orthopedic Surgery * Otolaryngology * Pathology * Pediatrics * Peripheral Vascular Disease * Physical Medicine and Rehabilitation * Physician Assistant * Plastic Surgery * Podiatry * Preventive Medicine * Psychologist * Psychiatrist * Pulmonary Disease * Radiation Oncology * Rheumatology * Speech Language Pathologist * Sports Medicine * Surgical Oncology * Thoracic Surgery * Urology * Vascular Surgery

        Desired Qualifications of Clinical Subcommittee Members:

        • Medical credentials relevant to the types of clinicians listed above
        • Familiarity with medical coding (ICD-10, HCPCS/CPT, DRG)
        • Board-certified or other professional certifications, as applicable
        • Experience treating Medicare patients

        Tasks and Expected Time Commitment for Clinical Subcommittee Members:

        Tasks for All Clinical Subcommittee Members

        2-4 hours to review Welcome Packet

        1 in-person meeting lasting about 4 hours, for all CS members for episode group selection in downtown Washington, D.C. in April 2018 (exact dates for each Subcommittee can be found on the nomination form here after February 9) (plus travel time)

        *Expected Time Commitment for Clinical Subcommittee Members who attend first in-person meeting = about 1.5 days total

        Tasks for Workgroup Members Only

        1 day-long in-person meeting for workgroup members only for episode group specification in downtown Washington, D.C. in May/June (exact dates to be determined) (plus travel time)

        2-4 hours to prepare for Service Assignment and Risk Adjustment Webinar

        2 hour Service Assignment and Risk Adjustment Webinar

        2-4 hours to prepare for Refinement Webinar

        2 hour Refinement Webinar

        *Expected Time Commitment for Workgroup Members Only = about 3 days total

        Required Information:

        Nominees are required to submit a completed MACRA Clinical Subcommittee Nomination Form. As part of this form, nominees are required to upload (i) a letter of interest (not to exceed two pages) highlighting experience/knowledge relevant to the expertise described above and involvement in measure development, and (ii) a curriculum vitae or summary of relevant experience (not to exceed 10 pages). If you wish to nominate yourself or other individuals for consideration, please complete the form by March 20, 2018 at midnight ET to be considered for participation in Wave 2. Nominees who submit their information after this date will enter a standing pool of nominees who may be selected for participation in condition- or procedure-specific workgroups convened within each Subcommittee.

        Contact Information:

        If you have any questions about the Clinical Subcommittees, the nomination process, or this project generally, please email macra-clinical-committee-support@acumenllc.com. If you would like to receive a 508-compliant PDF version of the nomination form for submission via email instead of the web-based form linked above, please email macra-clinical-committee-support@acumenllc.com to receive a blank form.

        Back to Top

        Quick Links

        Downloads

        Back to top

        .